Alan Redfern
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alan Redfern has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alexander T.J. Lee
The Christie NHS Foundation Trust, Manchester, United Kingdom
2 shared publications - Alexandra Clipson
Cancer Research UK National Biomarker Centre, University of Manchester, Manchester, UK
2 shared publications - Bernadette Brennan
Department of Paediatric Oncology, Royal Manchester Children's Hospital, Manchester, United Kingdom
2 shared publications - Caroline Dive
Cancer Research UK National Biomarker Centre, University of Manchester, Manchester, UK
2 shared publications - Dominic G. Rothwell
Cancer Research UK National Biomarker Centre, University of Manchester, Manchester, UK
2 shared publications - Florent Mouliere
Cancer Research UK National Biomarker Centre, University of Manchester, Manchester, UK
2 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (4) , 1342-1357
Cell-free DNA methylome and fragmentome analysis for relapse monitoring of Ewing sarcoma
Liquid biopsies and cell-free DNA (cfDNA) offer minimally invasive methods for the diagnosis and monitoring of Ewing Sarcoma (EwS). EwS have a low tumour mutational burden and their detection with plasma cfDNA is challenging. We hypothesised that analysing the cfDNA methylome and fragmentome could enhance sensitivity for detecting EwS and identifying disease recurrence. Using T7-MBD-seq, we conducted whole-genome and methylome sequencing of cfDNA from 87 serial samples of 23 patients with EwS and 3 patients with CIC-rearranged sarcoma (CIC). With EwingSign, a new machine learning model, we identified EwS or CIC in a test set for 11 out of 16 patients at diagnosis and 15 out of 18 clinically confirmed relapse events. 0 out of 24 non-cancer controls (NCC) were detected positive with EwingSign. When combined with global and regional fragmentome analysis, all 18 relapse cases were detected, with 15/18 detected by 2 or more modalities, and 1 out of 24 NCC was detected by one modality. These findings indicate that cfDNA methylome and fragmentome analysis, if validated in a larger cohort, could improve disease detection, monitoring and relapse identification in patients with EwS.
- 6 March 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (4) , 1342-1357
Open AccessCell-free DNA methylome and fragmentome analysis for relapse monitoring of Ewing sarcoma
Liquid biopsies and cell-free DNA (cfDNA) offer minimally invasive methods for the diagnosis and monitoring of Ewing Sarcoma (EwS). EwS have a low tumour mutational burden and their detection with plasma cfDNA is challenging. We hypothesised that analysing the cfDNA methylome and fragmentome could enhance sensitivity for detecting EwS and identifying disease recurrence. Using T7-MBD-seq, we conducted whole-genome and methylome sequencing of cfDNA from 87 serial samples of 23 patients with EwS and 3 patients with CIC-rearranged sarcoma (CIC). With EwingSign, a new machine learning model, we identified EwS or CIC in a test set for 11 out of 16 patients at diagnosis and 15 out of 18 clinically confirmed relapse events. 0 out of 24 non-cancer controls (NCC) were detected positive with EwingSign. When combined with global and regional fragmentome analysis, all 18 relapse cases were detected, with 15/18 detected by 2 or more modalities, and 1 out of 24 NCC was detected by one modality. These findings indicate that cfDNA methylome and fragmentome analysis, if validated in a larger cohort, could improve disease detection, monitoring and relapse identification in patients with EwS.
- Open Access
Cell-free DNA methylome and fragmentome analysis for disease relapse monitoring in patients with Ewing Sarcoma
Summary: Liquid biopsies and cell-free DNA (cfDNA) offer minimally invasive methods for the diagnosis and monitoring of Ewing Sarcoma (EwS). EwS have a low tumour mutational burden and their detection with plasma cfDNA is challenging. We hypothesised that analysing the cfDNA methylome and fragmentome could enhance sensitivity for detecting EwS and identifying early disease recurrence. We conducted whole-genome and methylome sequencing of cfDNA from 68 serial samples of 15 patients with EwS and 3 patients with CIC-rearranged sarcoma (CIC). With EwingSign, a new machine learning model, we identified EwS or CIC in a test set for 10 out of 12 patients at diagnosis and 15 out of 18 clinically confirmed relapse events. 0 out of 29 non-cancer controls were detected positive with EwingSign. These findings indicate that cfDNA methylome and fragmentome analysis, if validated in a larger cohort, could improve disease detection, monitoring and relapse identification in patients with EwS.
Open AccessCell-free DNA methylome and fragmentome analysis for disease relapse monitoring in patients with Ewing Sarcoma
Summary: Liquid biopsies and cell-free DNA (cfDNA) offer minimally invasive methods for the diagnosis and monitoring of Ewing Sarcoma (EwS). EwS have a low tumour mutational burden and their detection with plasma cfDNA is challenging. We hypothesised that analysing the cfDNA methylome and fragmentome could enhance sensitivity for detecting EwS and identifying early disease recurrence. We conducted whole-genome and methylome sequencing of cfDNA from 68 serial samples of 15 patients with EwS and 3 patients with CIC-rearranged sarcoma (CIC). With EwingSign, a new machine learning model, we identified EwS or CIC in a test set for 10 out of 12 patients at diagnosis and 15 out of 18 clinically confirmed relapse events. 0 out of 29 non-cancer controls were detected positive with EwingSign. These findings indicate that cfDNA methylome and fragmentome analysis, if validated in a larger cohort, could improve disease detection, monitoring and relapse identification in patients with EwS.